Effect of fetal neural transplants inpatients with Huntington's disease 6 years after surgery:: a long-term follow-up study

被引:236
作者
Bachoud-Lévi, AC
Gaura, V
Brugières, P
Lefaucheur, JP
Boissé, MF
Maison, P
Baudic, S
Ribeiro, MJ
Bourdet, C
Remy, P
Cesaro, P
Hantraye, P
Peschanski, M
机构
[1] Fac Med, INSERM, U421, Creteil, France
[2] CHU Henri Mondor, Neurol Serv, F-94010 Creteil, France
[3] ENS, DEC, F-75230 Paris 05, France
[4] CEA, Serv Hosp Frederic Joliot, CNRS, URA 2210, F-91406 Orsay, France
[5] CHU Henri Mondor, Serv Neuroradiol, F-94010 Creteil, France
[6] CHU Henri Mondor, Serv Explorat Fonct, F-94010 Creteil, France
关键词
D O I
10.1016/S1474-4422(06)70381-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Although we have shown in three out of five patients with Huntington's disease that motor and cognitive improvements 2 years after intracerebral fetal neural grafts are correlated with recovery of brain metabolic activity in grafted striatal areas and connected regions of the cerebral cortex, neural grafts are not known to have Protective effects on the host brain per se. We undertook long-term follow-up of previously reported patients with the disease to ascertain the nature and extent of any secondary decline after grafting. Methods Five patients with Huntington's disease from our pilot study were assessed annually with the unified Huntington's disease rating scale, neuropsychological tests, and MRI, for up to 6 years after neural grafting. Resting cerebral activity was recorded at 2 and 6 years. Findings Clinical improvement plateaued after 2 years and then faded off variably 4-6 years after surgery. Dystonia deteriorated consistently, whereas chorea did not. Cognitive performance remained stable on non-timed tests, whereas progression of motor disability was shown by deterioration on timed tests. Hypometabolism also affected the brain heterogeneously, sparing the benefits in the frontal cortex and at the precise location of the grafts, but showing a progressive deterioration in other areas. Two patients who had no benefit from grafting at 2 years continued to decline in the same way as non-grafted patients. Interpretation Neuronal transplantation in Huntington's disease provides a period of several years of improvement and stability, but not a permanent cure for the disease. Improvement of the surgical procedure and in patient selection could improve the therapeutic value, but neuroprotective treatment seems to be unavoidable in the disease.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 18 条
  • [1] Motor and cognitive improvements in patients with Huntington's disease after neural transplantation
    Bachoud-Lévi, A
    Rémy, P
    Nguyen, JP
    Brugières, P
    Lefaucheur, JP
    Bourdet, C
    Baudic, S
    Gaura, V
    Maison, P
    Haddad, B
    Boissé, MF
    Grandmougin, T
    Jény, R
    Bartolomeo, P
    Dalla Barba, G
    Degos, JD
    Lisovoski, F
    Ergis, AM
    Pailhous, E
    Cesaro, P
    Hantraye, P
    Peschanski, M
    [J]. LANCET, 2000, 356 (9246) : 1975 - 1979
  • [2] Fetal neural grafts for Huntington's disease:: A prospective view
    Bachoud-Lévi, AC
    Hantraye, P
    Peschanski, M
    [J]. MOVEMENT DISORDERS, 2002, 17 (03) : 439 - 444
  • [3] Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease
    Bachoud-Lévi, AC
    Bourdet, C
    Brugières, P
    Nguyen, JP
    Grandmougin, T
    Haddad, B
    Jény, R
    Bartolomeo, P
    Boissé, MF
    Dalla Barba, G
    Degos, JD
    Ergis, AM
    Lefaucheur, JP
    Lisovoski, F
    Pailhous, E
    Rémy, P
    Palfi, S
    Defer, GL
    Cesaro, P
    Hantraye, P
    Peschanski, M
    [J]. EXPERIMENTAL NEUROLOGY, 2000, 161 (01) : 194 - 202
  • [4] Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF
    Bachoud-Lévi, AC
    Déglon, N
    Nguyen, JP
    Bloch, J
    Bourdet, C
    Winkel, L
    Rémy, P
    Goddard, M
    Lefaucheur, JP
    Brugières, P
    Baudic, S
    Cesaro, P
    Peschanski, M
    Aebischer, P
    [J]. HUMAN GENE THERAPY, 2000, 11 (12) : 1723 - 1729
  • [5] Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor:: Results of a phase I study
    Bloch, J
    Bachoud-Lévi, AC
    Déglon, N
    Lefaucheur, JP
    Winkel, L
    Palfi, S
    Nguyen, JP
    Bourdet, C
    Gaura, V
    Remy, P
    Brugières, P
    Boisse, MF
    Baudic, S
    Cesaro, P
    Hantraye, P
    Aebischer, P
    Peschanski, M
    [J]. HUMAN GENE THERAPY, 2004, 15 (10) : 968 - 975
  • [6] Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology
    Freeman, TB
    Cicchetti, F
    Hauser, RA
    Deacon, TW
    Li, XJ
    Hersch, SM
    Nauert, GM
    Sanberg, PR
    Kordower, JH
    Saporta, S
    Isacson, O
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (25) : 13877 - 13882
  • [7] Positron emission tomography after fetal transplantation in Huntington's disease
    Furtado, S
    Sossi, V
    Hauser, RA
    Samii, A
    Schulzer, M
    Murphy, CB
    Freeman, TB
    Stoessl, AJ
    [J]. ANNALS OF NEUROLOGY, 2005, 58 (02) : 331 - 337
  • [8] Striatal neural grafting improves cortical metabolism in Huntington's disease patients
    Gaura, V
    Bachoud-Lévi, AC
    Ribeiro, MJ
    Nguyen, JP
    Frouin, V
    Baudic, S
    Brugières, P
    Mangin, JF
    Boissé, MF
    Palfi, S
    Cesaro, P
    Samson, Y
    Hantraye, P
    Peschanski, M
    Remy, P
    [J]. BRAIN, 2004, 127 : 65 - 72
  • [9] Bilateral human fetal striatal transplantation in Huntington's disease
    Hauser, RA
    Furtado, S
    Cimino, CR
    Delgado, H
    Eichler, S
    Schwartz, S
    Scott, D
    Nauert, GM
    Soety, E
    Sossi, V
    Holt, DA
    Sanberg, PR
    Stoessl, AJ
    Freeman, TB
    [J]. NEUROLOGY, 2002, 58 (05) : 687 - 695
  • [10] *HUNT STUD GROUP, 2001, NEUROLOGY, V56, P1052